The Long Read / Norway: Unlocking Potential
Equality has long been a deeply held ideal in Norway, where the concept of allemannsretten – the legal right to…
GSK PLC
Last updated: 10.09.2018
GlaxoSmithKline plc (GSK) is a British pharmaceutical company headquartered in Brentford, London. Established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, GSK was the world’s sixth largest pharmaceutical company as of 2015, after Pfizer, Novartis, Merck, Hoffmann-La Roche and Sanofi. Emma Walmsley became CEO on 31 March 2017 and is the first female CEO of the company.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. As of August 2016 it had a market capitalisation of £81 billion (around $107 billion), the fourth largest on the London Stock Exchange. It has a secondary listing on the New York Stock Exchange.
GSK’s drugs and vaccines earned £21.3 billion in 2013.[7] Its top-selling products that year were Advair, Avodart, Flovent, Augmentin, Lovaza and Lamictal. GSK’s consumer products, which earned £5.2 billion in 2013, include Sensodyne and Aquafresh toothpaste, the malted-milk drink Horlicks, Abreva for cold sores, Breathe Right nasal strips, Nicoderm and Nicorette nicotine replacements, and Night Nurse, a cold remedy. The company developed the first malaria vaccine, RTS,S, which it said in 2014 it would make available for five percent above cost. Legacy products developed at GSK include several listed in the World Health Organization Model List of Essential Medicines, such as amoxicillin, mercaptopurine, pyrimethamine and zidovudine.
Related
Vaccines / An Expanded R&D Playbook
The story of how British doctor Edward Jenner serendipitously discovered a way to inoculate people against smallpox…
Vaccines / Top 4 Global Companies
Four companies (GSK, Pfizer, Sanofi, and MSD) together occupy over 80 percent of the global market for vaccines.…
Norway / Ahead of the Curve on Digitalisation
Many countries have struggled to adapt to the shift to remote working and digital communication brought about by…
Christian Probst – General Manager, GSK Norway
Christian Probst gives an overview of GSK Norway’s broad portfolio, market access hurdles, and the importance of…
Global / Top 10 PharmaBoardroom Interviews of 2020
2020 was a challenging year globally, but one in which the importance of the healthcare and life sciences sector…
GSK / 6 Key Takeaways from Vaccines Head Roger Connor at FT Conference
During the FT Global Pharmaceutical and Biotechnology Conference last week, GSK global vaccines president Roger…
The Long Read / Belgium: The Multifaceted
Squirreled away in the lowlands of North West Europe and somewhat dwarfed by the mighty neighbouring pharmaceutical…
GSK / Senior VP for Vaccines R&D on COVID-19 Collaboration
GSK, the world’s largest manufacturer of vaccines, has pursued a different strategy to that of its contemporaries…
Emmanuel Hanon – Senior VP, Vaccines R&D, GSK
In an exclusive interview, GSK’s Senior VP for Vaccines R&D Dr Emmanuel Hanon discusses how the sharing of…
Opinion / Addressing the Limitations of Today’s Approach to HTA
Mike Glover, Vice President Global Head of Access and Pricing Strategy Oncology at GSK outlines that while new…
COVID-19 Vaccines / AstraZeneca, GSK, J&J & Pfizer Execs’ Key Concerns
During the 28 May 2020 IFPMA media briefing on COVID-19 vaccines, four of the pharmaceutical industry’s leading…
